Related references
Note: Only part of the references are listed.Species-Specific Antifungal Susceptibility Patterns of Scedosporium and Pseudallescheria Species
Michaela Lackner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Population Pharmacokinetics of Conventional and Intermittent Dosing of Liposomal Amphotericin B in Adults: a First Critical Step for Rational Design of Innovative Regimens
William W. Hope et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012
Nkechi Azie et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2012)
Leishmaniasis impact and treatment access
M. den Boer et al.
CLINICAL MICROBIOLOGY AND INFECTION (2011)
Invasive Non-Aspergillus Mold Infections in Transplant Recipients, United States, 2001-2006
Benjamin J. Park et al.
EMERGING INFECTIOUS DISEASES (2011)
Comparison of 2 Doses of Liposomal Amphotericin B and Conventional Amphotericin B Deoxycholate for Treatment of AIDS-Associated Acute Cryptococcal Meningitis: A Randomized, Double-Blind Clinical Trial of Efficacy and Safety
Richard J. Hamill et al.
CLINICAL INFECTIOUS DISEASES (2010)
Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database
Dimitrios P. Kontoyiannis et al.
CLINICAL INFECTIOUS DISEASES (2010)
Drug-Induced Nephrotoxicity Caused by Amphotericin B Lipid Complex and Liposomal Amphotericin B A Review and Meta-Analysis
Amar Safdar et al.
MEDICINE (2010)
Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India
Shyam Sundar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Liposomal Amphotericin B A Review of its Use as Empirical Therapy in Febrile Neutropenia and in the Treatment of Invasive Fungal Infections
Marit D. Moen et al.
DRUGS (2009)
Bloodstream Infections Due to Trichosporon spp.: Species Distribution, Trichosporon asahii Genotypes Determined on the Basis of Ribosomal DNA Intergenic Spacer 1 Sequencing, and Antifungal Susceptibility Testing
Thomas C. Chagas-Neto et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2009)
Immunopharmacology of modern antifungals
R. Ben-Ami et al.
CLINICAL INFECTIOUS DISEASES (2008)
Amphotericin B lipid preparations: what are the differences?
J. P. Adler-Moore et al.
CLINICAL MICROBIOLOGY AND INFECTION (2008)
Update on the genus Trichosporon
Thomas C. Chagas-Neto et al.
MYCOPATHOLOGIA (2008)
Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)
Oliver A. Cornely et al.
CLINICAL INFECTIOUS DISEASES (2007)
Liposomal amphotericin B for the treatment of visceral leishmaniasis
Caryn Bern et al.
CLINICAL INFECTIOUS DISEASES (2006)
Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion
Helene Vogelsinger et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis (vol 24, pg 119, 2005)
SB Girois et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2006)
Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis
J Gavaldà et al.
CLINICAL MICROBIOLOGY AND INFECTION (2005)
Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B
M Simitsopoulou et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4
S Bellocchio et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Efficacy, safety and costeffectiveness of amphotericin B lipid complex (ABLC): a review of the literature
R Martino
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Low-dose amphotericin b lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies -: a randomized, controlled trial
M Subirà et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2004)
The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism
K Sau et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations
JP Barrett et al.
CLINICAL THERAPEUTICS (2003)
Variability in polyene content and cellular toxicity among deoxycholate amphotericin B formulations
JD Cleary et al.
PHARMACOTHERAPY (2003)
Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis
MT Martin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity
S Harbarth et al.
CLINICAL INFECTIOUS DISEASES (2002)
A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients
R Bowden et al.
CLINICAL INFECTIOUS DISEASES (2002)
Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS
PC Johnson et al.
ANNALS OF INTERNAL MEDICINE (2002)
Overview of the lipid formulations of amphotericin B
B Dupont
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2002)
Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate
I Bekersky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi:: Maximum tolerated dose study
TJ Walsh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Fungal phospholipase activity and susceptibility to lipid preparations of amphotericin B
M Gottfredsson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Mortality and costs of acute renal failure associated with amphotericin B therapy
DW Bates et al.
CLINICAL INFECTIOUS DISEASES (2001)
Lipid-based amphotericin B: a review of the last 10 years of use
IM Hann et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2001)
Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia
RV Fleming et al.
LEUKEMIA & LYMPHOMA (2001)
A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia
JR Wingard et al.
CLINICAL INFECTIOUS DISEASES (2000)
Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system
AH Groll et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients:: data of a prematurely stopped clinical trial
GJ Timmers et al.
BONE MARROW TRANSPLANTATION (2000)
Share Paper
